Back to mobile site
Get it on Google Play

Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA

October 5, 2026 7:00 AM EDT Send to a Friend
Stoke Therapeutics (Nasdaq: STOK) announced it has completed a meeting with the U.S. Food and Drug Administration to align on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login